Australian research makes breakthrough in boosting breast cancer cure rate
Australian researchers have made a breakthrough in improving the cure rate for the most common form of breast cancer. An ...
Replimune Group’s Promising Outlook: FDA Priority Review and Positive Trial Data Support Buy Rating
Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday.Invest with ...
Medscape10h
How New Research Is Redefining Melanoma Treatment
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
Targeted Oncology17h
Beckermann and Participants Discuss Second-Line ccRCC Options
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
Managed Healthcare Executive18h
BLA Accepted for Melanoma Combination Therapy, RP1 and Nivolumab
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
The Pharma Letter1d
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
NZ Doctor1d
Consultations for cancer and ADHD medicines close soon
Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is considering changes to the regulations and funding restrictions stimulant ...
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...
Targeted Oncology1d
FDA Accepts BLA for RP1 With Nivolumab in Advanced Melanoma
The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Evolus Inc EOLS shares jumped 35.6% to $14.25 after the company announced it expects FDA approval for Evolysse gels within 90 ...
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...